Engineering bacteriophage nanocarriers for targeted delivery of protein reagents to prostate cancer cells
Proteinaceous reagents, including antibodies and synthetic proteins, have become some of the most effective reagents for targeted treatment and diagnosis of disease. The unique catalytic activity of some proteins and ability to bind disease-relevant receptors that can evade small molecule discovery, make these reagents well suited for use as therapeutic and bioimaging reagents. However, the large size and charge distribution of most proteins greatly inhibits their intracellular delivery to diseased cells, limiting targets to those displayed on the cell surface. In response to this challenge, we ...
(For more, see "View full record.")